📣 VC round data is live. Check it out!

Solid Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Solid Biosciences and similar public comparables like Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma and more.

Solid Biosciences Overview

About Solid Biosciences

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.


Founded

2013

HQ

United States

Employees

100

Financials (LTM)

Revenue:
EBITDA: ($193M)

EV

$545M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Solid Biosciences Financials

Solid Biosciences reported last 12-month revenue of — and negative EBITDA of ($193M).

In the same LTM period, Solid Biosciences generated — in gross profit, ($193M) in EBITDA losses, and had net loss of ($184M).

Revenue (LTM)


Solid Biosciences P&L

In the most recent fiscal year, Solid Biosciences reported revenue of and EBITDA of ($178M).

Solid Biosciences is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Solid Biosciences
LTMLast FY202320242025202620272028
EBITDA($193M)($178M)($102M)($122M)($178M)
Net Profit($184M)($174M)($96M)($125M)($174M)

Financial data powered by Morningstar, Inc.

Solid Biosciences Stock Performance

Solid Biosciences has current market cap of $712M, and enterprise value of $545M.

Market Cap Evolution


Solid Biosciences' stock price is $7.23.

Solid Biosciences share price decreased by 0.4% in the last 30 days, and increased by 125.2% in the last year.

Solid Biosciences has an EPS (earnings per share) of $-1.77.

See more trading valuation data for Solid Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$545M$712M1.4%-0.4%16.4%125.2%$-1.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Solid Biosciences Valuation Multiples

Solid Biosciences trades at (2.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Solid Biosciences

EV / Revenue (LTM)


Solid Biosciences Financial Valuation Multiples

As of May 5, 2026, Solid Biosciences has market cap of $712M and EV of $545M.

Solid Biosciences has a P/E ratio of (3.9x).

LTMLast FY202320242025202620272028
EV/EBITDA(2.8x)(3.1x)(5.4x)(4.5x)(3.1x)
EV/EBIT(2.9x)(3.0x)(5.2x)(4.2x)(3.0x)
P/E(3.9x)(4.1x)(7.4x)(5.7x)(4.1x)
EV/FCF(5.6x)(3.5x)(5.7x)(5.4x)(3.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Solid Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Solid Biosciences Margins & Growth Rates

See estimated margins and future growth rates for Solid Biosciences

Solid Biosciences Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth20%46%
EBIT Growth24%38%
Net Profit Growth30%40%
FCF Growth5%56%

Data powered by FactSet, Inc. and Morningstar, Inc.

Solid Biosciences Operational KPIs

Solid Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.

Access forward-looking KPIs for Solid Biosciences
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.8M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Solid Biosciences Competitors

Solid Biosciences competitors include Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma, Arvinas, Alkaloid, Bioage Labs, BridgeBio Oncology, Guizhou Sanli and Ironwood Pharmaceuticals.

Most Solid Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Zentiva2.8x9.8x
Astria Therapeutics
Lexicon Pharmaceuticals13.6x15.2x(16.3x)(12.0x)
Vor Biopharma(0.7x)(0.9x)
Arvinas0.1x0.1x(0.2x)(0.1x)
Alkaloid2.0x19.3x
Bioage Labs51.3x61.7x(5.8x)(4.5x)
BridgeBio Oncology(1.8x)(1.6x)

This data is available for Pro users. Sign up to see all Solid Biosciences competitors and their valuation data.

Start Free Trial

Solid Biosciences Funding History

Before going public, Solid Biosciences raised $93M in total equity funding, across 2 rounds.


Solid Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-17Series CBain Capital Life Sciences; Biogen; Cormorant Asset Management; Foresite Capital; Janus Capital Group; Leerink Partners; Perceptive Advisors; RA Capital Management; RTW Investments$50MSolid Biosciences, a biotech company developing gene therapies for Duchenne muscular dystrophy (DMD), completed the initial closing of its $50 million Series C financing on March 30, 2017. The round was led by Bain Capital Life Sciences and RA Capital Management, with participation from RTW Investments, Foresite Capital, Cormorant Asset Management, entities affiliated with Leerink Partners, Perceptive Advisors, Janus Capital Management, and Biogen. Proceeds were earmarked to advance its investigational gene therapy SGT-001 into clinical trials in the second half of 2017, secure manufacturing capacity, and build its pipeline with next-generation gene therapy assets and disease-modifying therapies. As part of the transaction, Solid Biosciences merged with its gene therapy subsidiary Solid GT, consolidating boards and aligning resources, with RA's Rajeev Shah and Bain's Adam M. Koppel joining the board. The company focused on innovative biological products targeting unmet needs in DMD, including dual-route delivery systems in later programs. Bain Capital Life Sciences, led by former Biogen executive Adam Koppel, had recently raised a $720 million fund, marking its entry into biotech investments, with Solid Biosciences as an early deployment alongside other local biotechs. Solid Biosciences remained pre-revenue as a clinical-stage gene therapy developer in 2017, with 2020 revenue later reported at $3.34 million.
Nov-15Series BPerceptive Advisors$43M

Solid Biosciences M&A Activity

Solid Biosciences has acquired 1 company to date.

Last acquisition by Solid Biosciences was on September 30th 2022. Solid Biosciences acquired AavantiBio for $75M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Solid Biosciences

AavantiBio
Description
AavantiBio is a Waltham, Massachusetts-based biopharmaceutical company advancing AAV gene therapies and editing technologies for central nervous system disorders like frontotemporal dementia and rare epilepsies. It focuses on delivering oversized transgenes via proprietary capsids.
HQ CountryUnited States
HQ City
Deal Date30 Sep 2022
Valuation$75M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Solid Biosciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Solid Biosciences

When was Solid Biosciences founded?Solid Biosciences was founded in 2013.
Where is Solid Biosciences headquartered?Solid Biosciences is headquartered in United States.
How many employees does Solid Biosciences have?As of today, Solid Biosciences has over 100 employees.
Who is the CEO of Solid Biosciences?Solid Biosciences' CEO is Alexander G. Cumbo.
Is Solid Biosciences publicly listed?Yes, Solid Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Solid Biosciences?Solid Biosciences trades under SLDB ticker.
When did Solid Biosciences go public?Solid Biosciences went public in 2018.
Who are competitors of Solid Biosciences?Solid Biosciences main competitors include Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma, Arvinas, Alkaloid, Bioage Labs, BridgeBio Oncology, Guizhou Sanli, Ironwood Pharmaceuticals.
What is the current market cap of Solid Biosciences?Solid Biosciences' current market cap is $712M.
Is Solid Biosciences profitable?No, Solid Biosciences is not profitable.
What is the current EBITDA of Solid Biosciences?Solid Biosciences has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Solid Biosciences?Current EBITDA multiple of Solid Biosciences is (2.8x).
What is the current FCF of Solid Biosciences?Solid Biosciences' last 12 months FCF is ($98M).
What is the current EV/FCF multiple of Solid Biosciences?Current FCF multiple of Solid Biosciences is (5.6x).
How many companies Solid Biosciences has acquired to date?As of May 2026, Solid Biosciences has acquired 1 company.
What was the largest acquisition by Solid Biosciences?$75M acquisition of AavantiBio on 30th September 2022 was the largest M&A Solid Biosciences has done to date.
What companies Solid Biosciences acquired?Solid Biosciences acquired AavantiBio.
In how many companies Solid Biosciences has invested to date?Solid Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Solid Biosciences

Lists including Solid Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial